blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP1702920

EP1702920 - Pyrazole compounds useful as protein kinase inhibitors [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  17.08.2012
Database last updated on 30.10.2024
Most recent event   Tooltip27.09.2013Lapse of the patent in a contracting state
New state(s): TR
published on 30.10.2013  [2013/44]
Applicant(s)For all designated states
VERTEX PHARMACEUTICALS INCORPORATED
130 Waverly Street
Cambridge, MA 02139-4242 / US
[2006/38]
Inventor(s)01 / Bebbington, David
6 Linden Close
Newbury Berkshire RG14 1QA / GB
02 / Charrier, Jean-Damien
Vertex Pharmaceuticals Inc.
Cottage Wing
Station Road
Bishops Itchington, Southam, Oxfordshire CV47 2QB / GB
03 / Golec, Julian
8 Manor Farm
Chapel Road
Ashbury Wiltshire SN6 8LS / GB
04 / Miller, Andrew
Cherry Cottage
Chilton Road
Upton
Didcot Oxfordshire OX11 9JL / GB
05 / Knegtel, Ronald
3 Bath Court
Bath Street
Abingdon
Oxfordshire OX1X 1EE / GB
 [2011/40]
Former [2006/38]01 / Bebbington, David
6 Linden Close
Newbury Berkshire RG 14 QA / GB
02 / Charrier, Jean-Damien
Vertex Pharma. Inc Cottage Wing Station Rd Southam
Bishops Itchington Oxfordshire CV47 2QB / GB
03 / Golec, Julian
8 Manor Farm Chapel Road
Ashbury Wiltshire SN6 8LS / GB
04 / Miller, Andrew
Cherry Cottage Chilton Road Upton
Didcot Oxfordshire OX11 9JL / GB
05 / Knegtel, Ronald
3 Bath Court Bath Street Abingdon
Oxfordshire OX1X 1EE / GB
Representative(s)Cornish, Kristina Victoria Joy, et al
Kilburn & Strode LLP
Lacon London
84 Theobalds Road
London WC1X 8NL / GB
[N/P]
Former [2006/38]Cornish, Kristina Victoria Joy, et al
Kilburn & Strode, 20 Red Lion Street
London WC1R 4PJ / GB
Application number, filing date06011799.119.12.2001
[2006/38]
Priority number, dateUS20000257887P21.12.2000         Original published format: US 257887 P
US20010286949P27.04.2001         Original published format: US 286949 P
[2006/38]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP1702920
Date:20.09.2006
Language:EN
[2006/38]
Type: B1 Patent specification 
No.:EP1702920
Date:12.10.2011
Language:EN
[2011/41]
Search report(s)(Supplementary) European search report - dispatched on:EP14.08.2006
ClassificationIPC:C07D403/12, C07D401/14, A61K31/506, A61P35/00
[2006/38]
CPC:
C07D403/14 (EP,US); C07D401/12 (EP,KR,US); A61P1/00 (EP);
A61P11/06 (EP); A61P13/12 (EP); A61P15/00 (EP);
A61P17/06 (EP); A61P17/14 (EP); A61P19/02 (EP);
A61P19/08 (EP); A61P19/10 (EP); A61P21/00 (EP);
A61P21/02 (EP); A61P21/04 (EP); A61P25/00 (EP);
A61P25/02 (EP); A61P25/14 (EP); A61P25/16 (EP);
A61P25/18 (EP); A61P25/24 (EP); A61P25/28 (EP);
A61P27/02 (EP); A61P29/00 (EP); A61P3/08 (EP);
A61P3/10 (EP); A61P3/14 (EP); A61P31/12 (EP);
A61P31/18 (EP); A61P31/20 (EP); A61P31/22 (EP);
A61P35/00 (EP); A61P35/02 (EP); A61P35/04 (EP);
A61P37/00 (EP); A61P37/02 (EP); A61P37/06 (EP);
A61P37/08 (EP); A61P43/00 (EP); A61P5/00 (EP);
A61P5/18 (EP); A61P9/00 (EP); A61P9/04 (EP);
A61P9/08 (EP); A61P9/10 (EP); C07D231/12 (EP,US);
C07D233/56 (EP,US); C07D249/08 (EP,US); C07D401/14 (EP,US);
C07D403/12 (EP,US); C07D405/14 (EP,US); C07D407/14 (EP,US);
C07D409/14 (EP,US); C07D417/14 (EP,US); C07D471/04 (EP,US);
C07D473/16 (EP,US); C07D487/04 (EP,US); C07D491/04 (EP,US);
C07D493/04 (EP,US); C07D495/04 (EP,US); C07D513/04 (EP,US) (-)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   TR [2006/38]
Extension statesAL14.06.2006
LT14.06.2006
LV14.06.2006
MK14.06.2006
RO14.06.2006
SI14.06.2006
TitleGerman:Pyrazoleverbindungen als Protein-Kinasehemmer[2011/43]
English:Pyrazole compounds useful as protein kinase inhibitors[2006/38]
French:Composés de pyrazole utiles en tant qu'inhibiteurs de protéine kinase[2006/38]
Former [2006/38]Pyrazoleverbindungen als Protein- kinasehemmer
Examination procedure19.03.2007Examination requested  [2007/18]
29.06.2007Despatch of a communication from the examining division (Time limit: M06)
21.02.2008Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
25.04.2008Reply to a communication from the examining division
12.02.2010Despatch of a communication from the examining division (Time limit: M06)
19.08.2010Reply to a communication from the examining division
10.02.2011Communication of intention to grant the patent
11.05.2011Fee for grant paid
11.05.2011Fee for publishing/printing paid
Parent application(s)   TooltipEP01994323.2  / EP1353916
Divisional application(s)EP10184271.4  / EP2264028
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20010994323) is  29.01.2004
Opposition(s)13.07.2012No opposition filed within time limit [2012/38]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
28.04.2008Request for further processing filed
28.04.2008Full payment received (date of receipt of payment)
Request granted
29.05.2008Decision despatched
Fees paidRenewal fee
14.06.2006Renewal fee patent year 03
14.06.2006Renewal fee patent year 04
14.06.2006Renewal fee patent year 05
27.12.2006Renewal fee patent year 06
24.12.2007Renewal fee patent year 07
24.12.2008Renewal fee patent year 08
28.12.2009Renewal fee patent year 09
27.12.2010Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT12.10.2011
BE12.10.2011
CY12.10.2011
DK12.10.2011
FI12.10.2011
SE12.10.2011
TR12.10.2011
LU19.12.2011
CH31.12.2011
LI31.12.2011
MC31.12.2011
GR13.01.2012
PT13.02.2012
[2013/44]
Former [2013/29]AT12.10.2011
BE12.10.2011
CY12.10.2011
DK12.10.2011
FI12.10.2011
SE12.10.2011
LU19.12.2011
CH31.12.2011
LI31.12.2011
MC31.12.2011
GR13.01.2012
PT13.02.2012
Former [2013/25]AT12.10.2011
BE12.10.2011
CY12.10.2011
DK12.10.2011
SE12.10.2011
LU19.12.2011
CH31.12.2011
LI31.12.2011
MC31.12.2011
GR13.01.2012
PT13.02.2012
Former [2013/07]AT12.10.2011
BE12.10.2011
CY12.10.2011
DK12.10.2011
SE12.10.2011
CH31.12.2011
LI31.12.2011
MC31.12.2011
GR13.01.2012
PT13.02.2012
Former [2012/49]BE12.10.2011
CY12.10.2011
DK12.10.2011
SE12.10.2011
CH31.12.2011
LI31.12.2011
MC31.12.2011
GR13.01.2012
PT13.02.2012
Former [2012/35]BE12.10.2011
CY12.10.2011
DK12.10.2011
SE12.10.2011
MC31.12.2011
GR13.01.2012
PT13.02.2012
Former [2012/33]BE12.10.2011
CY12.10.2011
SE12.10.2011
MC31.12.2011
GR13.01.2012
PT13.02.2012
Former [2012/28]BE12.10.2011
CY12.10.2011
SE12.10.2011
GR13.01.2012
PT13.02.2012
Former [2012/24]BE12.10.2011
SE12.10.2011
GR13.01.2012
PT13.02.2012
Former [2012/23]BE12.10.2011
GR13.01.2012
PT13.02.2012
Former [2012/21]BE12.10.2011
Documents cited:Search[A]WO0021955  (ZENECA LTD [GB], et al) [A] 1,9* examples 16-20 *;
 [A]WO0039101  (ASTRAZENECA UK LTD [GB], et al) [A] 1,9 * examples 135,160,161 *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.